VCEL Stock Analysis: Vericel Ord | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.399m USD | 12M Return: 19.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 26.5M
Qual. Beats: 0
Rev. Trend: 99.5%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Vericel Corporation (NASDAQ: VCEL) is a commercial-stage biopharmaceutical company headquartered in Burlington, Massachusetts, that develops and markets autologous (patient-derived) cell therapy and specialty biologic products. Its portfolio targets two niche medical markets in North America: sports medicine, led by MACI, a cartilage repair product for knee defects, and severe burn care, which includes Epicel, a permanent skin replacement for deep-dermal and full-thickness burns, and NexoBrid, a biological product for eschar removal in burn patients. Originally incorporated in 1989 as Aastrom Biosciences, the company adopted the Vericel name in November 2014 and trades as a mid-cap stock in the biotechnology sub-industry of the healthcare sector. As a developer of autologous cellular therapies-a specialized segment of regenerative medicine-Vericel operates in a field where products are typically priced at a premium and require complex manufacturing logistics tied to patient-specific cell collection and delivery.
- MACI knee cartilage repair revenue sustains double-digit growth
- NexoBrid commercial launch expands total addressable burn care market
- Operating margin expands on higher manufacturing utilization and product mix
| Net Income: 21.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 1.64 > 1.0 |
| NWC/Revenue: 67.41% < 20% (prev 66.32%; Δ 1.10% < -1%) |
| CFO/TA 0.13 > 3% & CFO 61.7m > Net Income 21.5m |
| Net Debt (-50.8m) to EBITDA (35.3m): -1.44 < 3 |
| Current Ratio: 5.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.8m) vs 12m ago 1.74% < -2% |
| Gross Margin: 74.84% > 18% (prev 72.54%; Δ 2.30% > 0.5%) |
| Asset Turnover: 64.18% > 50% (prev 56.18%; Δ 8.00% > 0%) |
| Interest Coverage Ratio: 36.04 > 6 (EBIT TTM 23.0m / Interest Expense TTM 637k) |
| A: 0.41 (Total Current Assets 244.1m - Total Current Liabilities 47.2m) / Total Assets 485.6m |
| B: -0.79 (Retained Earnings -382.6m / Total Assets 485.6m) |
| C: 0.05 (EBIT TTM 23.0m / Avg Total Assets 455.1m) |
| D: 2.75 (Book Value of Equity 356.2m / Total Liabilities 129.4m) |
| Altman-Z'' = 3.32 = A |
| DSRI: 1.12 (Receivables 72.4m/52.9m, Revenue 292.1m/238.5m) |
| GMI: 0.97 (GM 72.54% / 74.84%) |
| AQI: 1.24 (AQ_t 0.15 / AQ_t-1 0.12) |
| SGI: 1.22 (Revenue 292.1m / 238.5m) |
| TATA: -0.08 (NI 21.5m - CFO 61.7m) / TA 485.6m) |
| Beneish M = -2.66 (Cap -4..+1) = A |
As of July 08, 2026, the stock is trading at USD 46.95 with a total of 422,919 shares traded. Over the past week, the price has changed by +4.17%, over one month by +31.26%, over three months by +40.86% and over the past year by +19.13%.
Current recommended Stop Loss: 44.50 (which is 5.2% or 1.4 ATR below the current price).
Vericel Ord has received a consensus analysts rating of 4.88. Therefore, it is recommended to buy VCEL.
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 55.4 | 18.1% |
P/E Trailing = 109.2558
P/E Forward = 95.2381
P/S = 8.214
P/B = 6.4726
Revenue TTM = 292.1m USD
EBIT TTM = 23.0m USD
EBITDA TTM = 35.3m USD
Long Term Debt = 80.4m USD (estimated: total debt 94.5m - short term 14.2m)
Short Term Debt = 14.2m USD (from shortTermDebt, last quarter)
Debt = 94.5m USD (from shortLongTermDebtTotal, last quarter) (leases 94.5m already included)
Net Debt = -50.8m USD (calculated: Debt 94.5m - CCE 145.3m)
Enterprise Value = 2.35b USD (2.40b + Debt 94.5m - CCE 145.3m)
Interest Coverage Ratio = 36.04 (Ebit TTM 23.0m / Interest Expense TTM 637k)
EV/FCF = 40.63x (Enterprise Value 2.35b / FCF TTM 57.8m)
FCF Yield = 2.46% (FCF TTM 57.8m / Enterprise Value 2.35b)
FCF Margin = 19.79% (FCF TTM 57.8m / Revenue TTM 292.1m)
Net Margin = 7.35% (Net Income TTM 21.5m / Revenue TTM 292.1m)
Gross Margin = 74.84% ((Revenue TTM 292.1m - Cost of Revenue TTM 73.5m) / Revenue TTM)
Gross Margin QoQ = 72.0% (prev 78.70%)
Tobins Q-Ratio = 4.84 (Enterprise Value 2.35b / Total Assets 485.6m)
Interest Expense / Debt = 0.67% (Interest Expense 637k / Debt 94.5m)
Taxrate = 4.94% (859k / 17.4m)
NOPAT = 21.8m (EBIT 23.0m * (1 - 4.94%))
Current Ratio = 5.18 (Total Current Assets 244.1m / Total Current Liabilities 47.2m)
Debt / Equity = 0.27 (Debt 94.5m / totalStockholderEquity, last quarter 356.2m)
Debt / EBITDA = -1.44 (Net Debt -50.8m / EBITDA 35.3m)
Debt / FCF = -0.88 (Net Debt -50.8m / FCF TTM 57.8m)
Total Stockholder Equity = 334.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.72% (Net Income 21.5m / Total Assets 485.6m)
RoE = 6.41% (Net Income TTM 21.5m / Total Stockholder Equity 334.9m)
RoCE = 5.53% (EBIT 23.0m / Capital Employed (Equity 334.9m + L.T.Debt 80.4m))
RoIC = 4.98% (NOPAT 21.8m / Invested Capital 438.0m)
WACC = 9.04% (E(2.40b)/V(2.49b) * Re(9.37%) + D(94.5m)/V(2.49b) * Rd(0.67%) * (1-Tc(0.05)))
Discount Rate = 9.37% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 46.67 | Cagr: 0.23%
[DCF] Terminal Value 75.77% ; FCFF base≈52.1m ; Y1≈59.7m ; Y5≈87.9m
[DCF] Fair Price = 24.10 (EV 1.18b - Net Debt -50.8m = Equity 1.23b / Shares 51.1m; r=9.04% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.68 | # QB: 0
Revenue Correlation: 99.51 | Revenue CAGR: 18.60% | SUE: 2.66 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.03 | Chg30d=N/A | Revisions=+0% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.08 | Chg30d=-3.53% | Revisions=+25% | Analysts=5
EPS current Year (2026-12-31): EPS=0.45 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+41.2% | GrowthRev=+20.2%
EPS next Year (2027-12-31): EPS=0.85 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+88.5% | GrowthRev=+17.0%
[Analyst] Revisions Ratio: +50% (up=3, down=0)